An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations. This is a video synopsis/summary of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback